Clinical Trials in New York

Showing 9941-9960 of 22,668 trials

The Medtronic TAVR 2.0 US Clinical Study

NCT02738853

The study objective is to evaluate safety and efficacy of the Medtronic TAVR (Transcatheter Aortic Valve Replacement) 2.0 system in patients with severe symptomatic aortic stenosis who are considered at high through extreme risk for surgical aortic valve replacement

Aortic Valve Stenosis

Medtronic Cardiovascular93 participantsStarted Apr 2016

New Haven, Connecticut, United States • Kansas City, Kansas, United States • Boston, Massachusetts, United States +5 more locations

UNKNOWNNA< 1 mile

Evaluation of Efficacy and Safety of the triLift™ System

NCT05773924

Single center, single-arm, prospective, open Label with Before \& After Study Design.

Skin LaxityWrinkle

Lumenis Be Ltd.25 participantsStarted Feb 2023

New York, New York, United States

COMPLETEDPhase 1< 1 mile

(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies

NCT02561988

This is a Phase 1, open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of avapritinib (also known as BLU-285), administered orally (PO), in adult patients with advanced systemic mastocytosis and other relapsed or refractory myeloid malignancies. The study consists of 2 parts:, dose-escalation (Part 1) and expansion (Part 2).

Aggressive Systemic MastocytosisSystemic Mastocytosis-associated Hematologic Non-mast Cell DiseaseMast Cell Leukemia+1 more

Blueprint Medicines Corporation86 participantsStarted Mar 2016

Stanford, California, United States • Denver, Colorado, United States • Atlanta, Georgia, United States +8 more locations

The Medtronic TAVR 2.0 US Clinical Study

Evaluation of Efficacy and Safety of the triLift™ System

(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies

Find Trials by Condition in New York

Frequency of Methods of Local Invasion of Pancreatic Adenocarcinoma

First in Human Study of M4344 in Participants With Advanced Solid Tumors

Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer

Evaluation of QDOT MICRO™ Catheter for Pulmonary Vein Isolation in Subjects With Paroxysmal Atrial Fibrillation

FREEDOM COVID-19 Anticoagulation Strategy

Respiratory-gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) Study in Ulcerative Colitis

CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma

Transitional Care Model Evaluation 2020

Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL

Assessment of Safety and Efficacy of Nerivio for the Migraine Prevention

A Phase 2 Study of Axalimogene Filolisbac (ADXS11-001) in Participants With Carcinoma of the Anorectal Canal

A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model.

A Study to Evaluate the Dose Response Based on the Efficacy, Safety and Tolerability of Bimekizumab in Subjects With Active Psoriatic Arthritis Which is a Type of Inflammatory Arthritis

First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin

A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer

Narrow Band Imaging Project on Barrett's Esophagus

Diagnosis of Acid Reflux Disease Using Novel Imaging: A Prospective Study